A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

Also called NCT02097277

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 219 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02097277
Other papers using this trial's data
  • Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study Obesity (Silver Spring, Md.), 2019-01 DOI, PubMed 30520566, PMC6587787 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02097277. Randomized; double masking; primary purpose treatment. Start 2014-04-15 (actual); primary completion 2015-09-22 (actual). Results posted on 2019-05-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
Condition
Diabetes Mellitus Type 2
Intervention (Biological)
BMS-986036
Intervention (Biological)
Placebo (Matching with BMS-986036)
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct02097277
Content hash
65328b5f9fd707fa29d07420506442f45a9196f4a055b0244a74c26e4e435180